{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:39Z","timestamp":1792684599534,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    The current gold standard to prevent allograft rejection for maintenance immunosuppression in kidney transplantation currently consists in glucocorticoids, an antiproliferative agent and a calcineurin inhibitor (CNI), with better outcome for tacrolimus than cyclosporin. Although, CNI drastically improved early graft survival, so far, CNI have failed to significantly improve long-term survival mainly because of nephrotoxicity. In addition, CNI carry several other side effects such as an increased risk for cardiovascular events and for diabetes mellitus. Therefore, seeking alternatives to CNI remains of paramount importance in kidney transplantation. Belatacept is a fusion protein composed of the human IgG1 Fc fragment linked to the modified extracellular domain of cytotoxic T lymphocyte\u2013associated antigen 4. In kidney transplant recipients, pivotal phase III randomized studies suggested clinical benefits of belatacept as an initial maintenance regimen, as compared with cyclosporine, mainly on kidney function. Recently, a randomized study also suggested a clinical benefit on renal function of a conversion from a CNI-based to a belatacept-based maintenance regimen in patients. However, conversion from CNIs to belatacept is probably associated with an increased risk of biopsy-proven acute rejection and should prompt close clinical surveillance. On the other hand, other studies suggest a decrease in\n                    <jats:italic>de novo<\/jats:italic>\n                    humoral transplant immunization. Belatacept is probably associated with an increase in both risk and severity of some infectious diseases, including EBV-linked post-transplantation lymphoproliferative disorders, and with a decreased response to vaccines. Most studies on belatacept are observational, retrospective, and non-comparative. Consequently, high-quality data about the safety and efficacy profile of belatacept, as compared with the current gold standard for maintenance regimens (tacrolimus-based), is uncertain. Our review will therefore focus on the most recent published data aiming at evaluating the evidence-based or the \u201ctrue\u201d benefits and risks of belatacept-based regimens in kidney transplantation.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2022.942665","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T01:27:30Z","timestamp":1657762050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Yannis","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant."},{"key":"B4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept","volume":"12","author":"Archdeacon","year":"2012","journal-title":"Am J Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e14531","DOI":"10.1111\/ctr.14531","article-title":"Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States","volume":"36","author":"Karadkhele","year":"2022","journal-title":"Clin Transplant."},{"key":"B6","unstructured":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"B7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1111\/ajt.14452","article-title":"Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly","volume":"17","author":"Vincenti","year":"2017","journal-title":"Am J Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-Term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1097\/TP.0000000000001755","article-title":"A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation","volume":"101","author":"de Graav","year":"2017","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1111\/ajt.14377","article-title":"Lessons learned: early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using belatacept","volume":"17","author":"Newell","year":"2017","journal-title":"Am J Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/ajt.15817","article-title":"Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: results of a prospective, randomized clinical trial","volume":"20","author":"Stock","year":"2020","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1111\/ajt.16152","article-title":"Avoidance of CNI and steroids using belatacept-results of the clinical trials in organ transplantation 16 trial","volume":"20","author":"Mannon","year":"2020","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1111\/ajt.16538","article-title":"Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial","volume":"21","author":"Badell","year":"2021","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e052138","DOI":"10.1136\/bmjopen-2021-052138","article-title":"Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study","volume":"11","author":"Aubert","year":"2021","journal-title":"BMJ Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/TP.0000000000000159","article-title":"Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials","volume":"98","author":"Dobbels","year":"2014","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1111\/ajt.13853","article-title":"Comparison of utilization and clinical outcomes for belatacept- and tacrolimus-based immunosuppression in renal transplant recipients","volume":"16","author":"Wen","year":"2016","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1097\/TP.0000000000001589","article-title":"Belatacept compared with tacrolimus for kidney transplantation: a propensity score matched cohort study","volume":"101","author":"Cohen","year":"2017","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/ajt.16430","article-title":"Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept","volume":"21","author":"Chavarot","year":"2021","journal-title":"Am J Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1097\/TP.0000000000003824","article-title":"Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/jcm11061697","article-title":"Predictors of serological response to SARS-CoV-2 vaccination in kidney transplant patients: baseline characteristics, immunosuppression, and the role of IMPDH Monitoring","volume":"11","author":"Liefeldt","year":"2022","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/ajt.15220","article-title":"Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: a retrospective cohort analysis","volume":"19","author":"Viana","year":"2019","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/ajt.12721","article-title":"Kidney transplant recipients treated with belatacept exhibit increased na\u00efve and transitional B cells","volume":"14","author":"Leibler","year":"2014","journal-title":"Am J Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/ajt.15585","article-title":"The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients","volume":"20","author":"Parsons","year":"2020","journal-title":"Am J Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/jcm9113479","article-title":"Opportunistic infections and efficacy following conversion to belatacept-based therapy after kidney transplantation: a french multicenter cohort","volume":"9","author":"Bertrand","year":"2020","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.3390\/jcm10215159","article-title":"Belatacept use after kidney transplantation and its effects on risk of infection and COVID-19 vaccine response","volume":"10","author":"Terrec","year":"2021","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17028","article-title":"A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation","author":"Huang","year":"2022","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ajt.15584","article-title":"Belatacept-based immunosuppression: a calcineurin inhibitor-sparing regimen in heart transplant recipients","volume":"20","author":"Launay","year":"2020","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1111\/ajt.12863","article-title":"Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients","volume":"14","author":"Mujtaba","year":"2014","journal-title":"Am J Transplant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.942665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T01:27:33Z","timestamp":1657762053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.942665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":35,"alternative-id":["10.3389\/fmed.2022.942665"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.942665","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"942665"}}